Cellino Raises $80m Series A To Transform Stem Cell Therapy Manufacturing
Leaps By Bayer Is Lead Investor
Executive Summary
The Cambridge, MA start-up aims to ‘democratize’ therapies based on induced pluripotent stem cells by developing an automated manufacturing system.
You may also be interested in...
Bayer Consolidates Next-Generation Gene Editing Focus With Mammoth Deal
The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.
Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.
Why Tessera Believes Its Gene Writing Platform Can Go Way Beyond CRISPR
As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.